Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Galvokimig dose-ranging placebo-controlled study in adults with moderate to severe atopic dermatitis
2025-522578-35-00Phase 2Authorised
- Sponsor
- UCB
- Start
- Mar 2026
- Modality
- Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Galvokimig dose-ranging arm(s) with Placebo arm (2 arms). Primary endpoint: EASI75 response at Week 16. Planned start Mar 2026; status: authorised.
02
Drugs
galvokimig
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2025-522578-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522578-35-00.